An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer's disease

An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer's disease

IntroductionAging is the primary risk factor for sporadic Alzheimer's disease. Chronic low-grade inflammation associated with aging drives cognitive impairment through multiple mechanisms involving oxidative stress, insulin resistance, and dysregulation of metabolic, immunologic, and hematologi...

Full description

Saved in:
Bibliographic Details
Main Authors: Christopher L. Reading, Jiayan Yan, Marcia A. Testa, Donald C. Simonson, Hira Javaid, Lisa Schmunk, Daniel E. Martin-Herranz, Robert Brooke, Juozas Gordevicius, Jeffrey Zhang, Harvey Yuan, Clarence Ahlem, Lixia Wang, Penelope Markham, Nily Osman, Stephen O'Quinn, Joseph Palumbo
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Neuroscience
Subjects:
Alzheimer's
neuroinflammation
insulin
aging
DNA methylation
bezisterim
Online Access:https://www.frontiersin.org/articles/10.3389/fnins.2025.1516746/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fnins.2025.1516746/full

Similar Items